Piribedil therapy in Parkinson's disease. Use of the drug in the retard form.

Abstract

We conducted a 20-week nonblind study to evaluate the efficacy of piribedil in 30 patients with idiopathic Parkinson's disease (PD). Prior to the study 17 of these patients were under L-Dopa treatment alone or in combination with anticholinergics and/or amantadine, while 13 patients who had never taken L-Dopa were treated only with anticholinergics and/or amantadine, or were without any medication. Piribedil (in the retard form) was administered orally at a gradually increasing dose up to 200 mg daily, while previous antiparkinsonian medication remained unchanged. Twenty-five patients showed statistically significant improvement. Among the cardinal symptoms of parkinsonism, tremor responded the best. Depression also appeared to respond favorably. Our results indicate that piribedil may be a useful adjuvant in the treatment of PD.

• Authors: G Mentenopoulos, Z Katsarou, S Bostantjopoulou, J Logothetis
• Journal: Clinical neuropharmacology (Clin Neuropharmacol) Vol. 12 Issue 1 Pg. 23-8 (Feb 1989) ISSN: 0362-5664 [Print] United States
• PMID: 2713865 (Publication Type: Journal Article)

Chemical References

• Piperazines
• Piribedil

Topics

• Aged
• Drug Compounding
• Drug Evaluation
• Female
• Humans
• Male
• Middle Aged
• Parkinson Disease (drug therapy)
• Piperazines (therapeutic use)
• Piribedil (adverse effects, therapeutic use)